Dennis Henner is an Operating Partner in Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Prior to joining Blackstone he was co-founder and Managing Director of Clarus for 12 years beginning in 2005 with the firm's inception.
Dr, Henner has over 30 years of direct industry and investment experience within the healthcare sector, and has led investments in the biopharmaceutical sector including partnerships with pharmaceutical compaines. Prior to Clarus, Dr. Henner was a General Partner at MPM Capital, a healthcare venture capital firm. From 1981 to 2001, he was an executive at Genentech where he held various positions including Senior Vice President of Research, and was a member of Genentech's executive committee. Dr. Henner is currently a member of the Board of Directors for Cleave Biosciences, Forty Seven Inc. (NASDAQ: FTSV) and Imago.
Dr. Henner received his PhD from the Department of Microbiology at the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation. Dr. Henner is a member of the Board of Trustees of Reed College.